Uncommon Cents Investing LLC raised its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 3.0% during the fourth quarter, Holdings Channel reports. The firm owned 3,285 shares of the conglomerate’s stock after buying an additional 95 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Danaher were worth $754,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Fort Pitt Capital Group LLC raised its stake in Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock worth $66,194,000 after buying an additional 7,421 shares in the last quarter. Good Life Advisors LLC purchased a new position in shares of Danaher during the 3rd quarter worth approximately $217,000. ORG Partners LLC raised its position in shares of Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after acquiring an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. lifted its stake in shares of Danaher by 1.2% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock valued at $56,233,000 after purchasing an additional 2,465 shares during the period. Finally, Stifel Financial Corp boosted its position in shares of Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after purchasing an additional 11,216 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.
Danaher Price Performance
Shares of DHR opened at $238.41 on Monday. The firm has a market cap of $172.20 billion, a PE ratio of 45.50, a P/E/G ratio of 4.23 and a beta of 0.83. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a fifty day simple moving average of $234.85 and a two-hundred day simple moving average of $253.42.
Danaher Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio is currently 20.61%.
Wall Street Analyst Weigh In
DHR has been the subject of a number of research reports. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Robert W. Baird cut their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Scotiabank started coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $286.80.
View Our Latest Stock Analysis on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
- Five stocks we like better than Danaher
- Manufacturing Stocks Investing
- Unusual Call Option Volume in US Steel: Potential Upside Ahead?
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Energy Storage Stocks Charging the Renewable Energy Sector
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Telecom Titans: Comparing Verizon and AT&T for Growth Potential
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.